Meningococcal conjugate vaccines: Efficacy and new combinations

Jornal de Pediatria

Volumn 82, Issue SUPPL. 1, 2006, Pages

  Sáfadi, Marco Aurélio Palazzi ^a,b,c,g   Barros, Analíria Pimentel ^d,e,f  

^a FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^b Instituto de Saúde   (Brazil)

^c Hospital Sao Luiz   (Brazil)

^d UNIVERSIDADE DE PERNAMBUCO   (Brazil)

^e Sociedade Brasileira de Pediatria   (Brazil)

^f Departamento de Infectologia   (Brazil)

^g NONE   (Brazil)

Author keywords

Conjugate meningococcal vaccines; Meningococcal disease; Neisseria meningitidis

Indexed keywords

MENINGOCOCCUS VACCINE; NEISVAC C;

AGITATION; BRAZIL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CRYING; DISEASE CARRIER; DRUG EFFICACY; DRUG FORMULATION; FEVER; HEADACHE; HEALTH PROGRAM; HUMAN; IMMUNIZATION; IMMUNOLOGICAL MEMORY; INCIDENCE; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; IRRITABILITY; MASS IMMUNIZATION; MENINGOCOCCOSIS; MUSCLE HYPOTONIA; MYALGIA; NEISSERIA MENINGITIDIS; RASH; REVIEW; SEROTYPE; SIDE EFFECT; TREATMENT DURATION; VOMITING;

ADULT; BRAZIL; CHILD, PRESCHOOL; CLINICAL TRIALS; DISEASE OUTBREAKS; GREAT BRITAIN; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; INFANT; INFANT, NEWBORN; MASS IMMUNIZATION; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; POPULATION SURVEILLANCE; VACCINES, CONJUGATE;

EID: 33750511534     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/JPED.1495     Document Type: Review

References (70)

1. Word Health Organization. Control of meningococcal epidemic disease. WHO practical guidelines. 2nd ed. Geneva: World Health Organization; 1998. http://www.who.int/csr/resources/publications/meningitis/WHO_EMC_BAC_98_3_EN/en/ Access: 25/04/06.
2. Balmer P, Miller E. Meningococcal disease: how to prevent and how to manage. Curr Opin Infect Dis. 2002;15:275-81.
3. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunization campaign against meningococcal serogroup C disease in UK: a success story. Vaccine. 2001;20 Suppl 1:S58-67.
4. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364:365-7.
5. Granoff DM, Feavers IM, Borrow R. Meningococcal vaccines. In: Plotkin S, Orenstein WA, editors. Vaccines. 4th ed. Philadelphia: Elsevier; 2004. p. 959-88.
6. American Academy of Pediatrics. Meningococcal infections. In: Pickering LK, editor. 2003 red book: report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village: American Academy of Pediatrics; 2003. p. 430-6.
7. Hart CA, Rogers TR. Meningococcal disease. J Med Microbiol. 1993;39:3-25.
8. Word Health Organization (WHO) Working Group, Foundation Marcel Mérieux. Control of epidemic meningococcal disease. WHO practical guidelines. Lyon: Fondation Marcel Mérieux; 1995.
9. Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Center for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54:1-21.
10. Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines. Wkly Epidemiol Rec. 2002;77:331-9.
11. Peltola H, Kataja JM, Makela PH. Shift in the age-distribution of meningococcal disease as predictor of an epidemic? Lancet. 1982;2:595-7.
12. Centro de Vigilância Epidemiológica (CVE), Divisão de Doenças de Transmissão Respiratória. www.cve.saude.sp.gov. br. Access: 26/01/06.
13. Rosenstein N, Perkins B, Stephens D, Popovic T, Hughes J. Meningococcal disease. N Engl J Med. 2001;344:1378-88.
14. Connolly M, Noah N. Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993-6. European Meningitis Surveillance Group. Epidemiol Infect. 1999;122:41-9.
15. Noah N, Henderson B; Communicable Disease Surveillance Centre (PHLS). Surveillance of bacterial meningitis in Europe 1999/00. February, 2002. http://www.hpa.org.uk/hpa/inter/m_surveillance9900.pdf. Access: 20/04/06.
16. Rosenstein N, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis. 1999;180:1894-901.
17. Martin D, Lopez L, McDowell R. The epidemiology of meningococcal disease in New Zealand in 2004. Report prepared for the Ministry of Health by the Institute of Environmental Science and Research Limited. 2005. http://www.moh.govt.nz/moh.nsf/238fd5fb4fd051844c256669006aed57/. Access: 20/04/06.
18. Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D, et al. MeNZB™: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine. 2005;23:2191-6.
19. Moraes JC, Barata RB. A doença meningocócica em São Paulo, Brasil, no século XX: características epidemioló gicas Cad Saude Publica. 2005;21:1458-71.
20. Ministério da Saúde, Secretaria de Vigilância em Saúde. Boletim epidemiológico. Edição especial. 1999. http://dtr2001.saude.gov.br/svs/pub/pdfs/boletim_epi_edicao_ especial.pdf. Access: 20/04/06.
21. Lepow ML, Goldschneider I, Gold R, Randolph M, Gotschlich EC. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics. 1977;60:673-80.
22. Danzig L. Meningococcal vaccines. Pediatr Infect Dis J. 2004;23(12 Suppl):S285-92.
23. Lesinski GB, Westerink MA. Novel vaccine strategies to T-independent antigens. J Microbiol Methods. 2001;47:135-49.
24. Richmond P, Kaczmarski E, Borrow R, Findlow J, Clark S, McCann R, et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis. 2000;181:761-4.
25. MacLennan JM, Shackley F, Heath PT, Deeks JJ, Flamank C, Herbert M, et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA. 2000;283:2795-801.
26. Borrow R, Goldblatt D, Andrews N, Southern J, Ashton L, Deane S, et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis. 2002;186:1353-7.
27. McVernon J, Maclennan J, Buttery J, Oster P, Danzig L, Moxon ER. Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children. Pediatr Infect Dis J. 2002;21:747-53.
28. Rennels MB, Edwards KM, Keyserling HL, Reisinger K, Blatter MM, Quataert SA, et al. Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants. Pediatr Infect Dis J. 2001;20:153-9.
29. Richmond P, Borrow R, Miller E, Clark S, Sadler F, Fox A, et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis. 1999;179:1569-72.
30. Costantino P, Viti S, Podda A, Velmonte MA, Nencioni L, Rappuoli R. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine. 1992;10:691-8.
31. Twumasi PA Jr, Kumah S, Leach A, O'Dempsey TJ, Ceesay SJ, Todd J, et al. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis. 1995;171:632-8.
32. Leach A, Twumasi PA, Kumah S, Banya WS, Jaffar S, Forrest BD, et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis. 1997;175:200-4.
33. Borrow R, Longworth E, Gray SJ, Kaczmarski EB. Prevalence of de-O-acetylated serogroup C meningococci before the introduction of meningococcal serogroup C conjugate vaccines in the United Kingdom. FEMS Immunol Med Microbiol. 2000;28:189-91.
34. Arakere G, Frasch CE. Specificity of antibodies to O-acetyl-positive and O-acetyl-negative group C meningococcal polysaccharides in sera from vaccinees and carriers. Infect Immun. 1991;59:4349-56.
35. Richmond P, Borrow R, Findlow J, Martin S, Thornton C, Cartwright K, et al. Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and de-O-acetylated serogroup C strains. Infect Immun. 2001;69:2378-82.
36. Richmond P, Goldblatt D, Fusco PC, Fusco JD, Heron I, Clark S, et al. Safety and immunogenicity of a new Neisseria meningitidis serogroup C - tetanus toxoid conjugate vaccine in healthy adults. Vaccine. 1999;18;641-6.
37. Richmond P, Borrow R, Goldblatt D, Findlow J, Martin S, Morris R, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis. 2001;183:160-3.
38. Snape MD, Pollard AJ. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis. 2005;5:21-30.
39. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus, I: the role of humoral antibodies. J Exp Med. 1969;129:1307-26.
40. Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun. 2001;69:1568-73.
41. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diag Lab Immunol. 2003;10:780-6.
42. Lakshman R, Jones I, Walker D McMurtrie K, Shaw L, Race G, et al. Safety of a new conjugate meningococcal C vaccine in infants. Arch Dis Child. 2001;85:391-7.
43. Expert Working Group on Meningococcal. Group C conjugate vaccines. Safety of meningococcal group C conjugate vaccines. Curr Probl Pharmacovigilance. 2000;26:14.
44. Santos AG, Almeida FJ, Arnoni M, Sáfadi MAP, Sanajotta A, Lima R, et al. Eventos adversos da vacina conjugada contra o meningococo C. In: XIII Congresso Brasileiro de Infectologia Pediátrica; 2002; Salvador, Brasil.
45. Miller E, Southern J, Kitchin N, Cartwright K, Morris R, Burrage M, et al. Interactions between different meningococcal C conjugate vaccines and the Hib component of concomitantly administered diphtheria/tetanus/pertussis/ Hib vaccines with either whole cell or acellular pertussis antigens. In: Proceedings of the 21st Annual Meeting of the European Society of Pediatric Infectious Diseases; 2003; Sicily, Italy.
46. Southern J, Crowley-Luke A, Borrow R, Andrews N, Miller E. Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis containing DTP/Hib vaccine. Vaccine. 2006;24:215-9.
47. Buttery JP, Ridell A, McVernon J, Chantler T, Lane L, Bowen-Morris J, et al. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants. JAMA. 2005;293:1751-8.
48. Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol. 2002;51:717-22.
49. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326:365-6.
50. Maiden MC, Stuart JM; UK Meningococcal Carraige Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet. 2002;359:1829-31.
51. Health Protection Agency. Isolates, England and Wales, by region and group (by epidemiological year), 1989 to 2003. http://www.hpa.org.uk/infections/ topics_az/meningo/data_meni_t01.htm. Access: 25/04/06.
52. Perez-Trallero E, Vicente D, Montes M, Cisterna R. Positive effect of meningococcal C vaccination on serogroup replacement in Neisseria meningitidis. Lancet. 2002;360:953.
53. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364:365-7.
54. Snape MD, Kelly DF, Green B, Moxon ER, Borrow R, Pollard AJ. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J. 2005;24:128-31.
55. Borrow R, Goldblatt D, Finn A, Southern J, Ashton L, Andrews N, et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom. Infect Immun. 2003;71:5549-55.
56. Salleras L, Dominguez A, Cardenosa N. Impact of mass vaccination with polysaccharide conjugate vaccine against serogroup C meningococcal disease in Spain. Vaccine. 2003;21:725-8.
57. Cano R, Larrauri A, Mateo S, Alcala B, Salcedo C, Vazquez JA. Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. Euro Surveill. 2004;9:11-5.
58. de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van Derende A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup c conjugate vaccine in the Netherlands. Pediatr Infect Dis J. 2006;25:79-80.
59. United Kingdom, Department of Health. Planned changes to the routine Childhood Immunisation Programme. 2006. http://www.dh.gov.uk/ PublicationsAndStatistics/LettersAndCirculars/DearColleagueLetters/fs/en. Access: 10/2/2006.
60. Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease and the impact of serogroup C conjugate vaccination. Am J Epidemiol. 2005;162:89-100.
61. Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54:1-21.
62. Campbell JD, Edelman R, King JC Jr, Papa T, Ryall R, Rennels MB. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults. J Infect Dis. 2002;186:1848-51.
63. Rennels M, King J Jr, Ryall R, Papa T, Froeschle J. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J. 2004;23:429-35.
64. Centers for Disease Control and Prevention. Guillain-Barré syndrome among recipients of Menactra™ meningococcal conjugate vaccine - United States, June-July 2005. MMWR Dispatch. 2005;54:1-3.
65. Wyle FA, Artenstein MS, Brandt BL, Tramont EC, Kasper DL, Altieri PL, et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis. 1972;126:514-21.
66. Finne J, Leinonen M, Mäkelä PH. Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis. Lancet. 1983;2:355-7.
67. Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991;14:195-207.
68. Bjune G, Hoiby EA, Gronnesby JK, Arnesen O, Fredriksen JH, Halstensen A, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 1991;338:1093-6.
69. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine. 2001;19:2688-91.
70. de Moraes JC, Perkins BA, Camargo MC, Hidalgo NT, Barbosa HA, Sacchi CT, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 1992;340:1074-8.